{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Clivatuzumab",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1, with potential antineoplastic activity. Clivatuzumab binds to tumor cells expressing the MUC1 antigen and prevents MUC1-mediated signaling. MUC1, a mucin antigen, is overexpressed in pancreatic cancer but not in normal, healthy pancreatic cells.",
    "fdaUniiCode": "RGU8A332UL",
    "identifier": "C88638",
    "preferredName": "Clivatuzumab",
    "semanticType": "Immunologic Factor",
    "subclassOf": [
      "C29983"
    ],
    "synonyms": [
      "CLIVATUZUMAB",
      "Clivatuzumab"
    ]
  }
}